Not Signed In - Human Genome Sciences Announces Positive 76-Week Results Of Phase 2 Clinical Trial Of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Wed, 15 Nov 2006 08:00 AM EST
... Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the 76-week results of a Phase 2 clinical trial demonstrated that LymphoStat-B(TM) (belimumab) reduced disease activity in patients with serologically active systemic lupus erythematosus (SLE), exhibited durable biological activity, and appeared safe and well tolerated. [click link for full article] ...
Related Topics
- Clinical Trials
- Systemic Lupus Erythematosus
- Lupus
- Genes and Gene Therapy
- Systemic Lupus Erythematosus/sle
- Lupus Anticoagulant
- Fetal Development
- Cutaneous Lupus Erythematosus
- Drug-induced lupus erythematosus
- Psychopharmacology
- Systemic Lupus
- Human Genome Epidemiology Network
- Scleroderma
- Human Papilloma Virus
- Lupus Nephritis
- Growth Hormones
- Growth Hormone
- Pharmacology
- Human Papillomavirus
- Trastuzumab
email this page
print this page
bookmark this page
feedback on this page
